FPRX News Alert Five Prime Therapeutics Inc (FPRX) 26.12 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Five Prime Therapeutics Inc (FPRX) 26.12 $FPRX

MacroGenics Inks Deal with J&J for Blood Cancer Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 2:00PM CST
MacroGenics, Inc. (MGNX) entered into a collaboration and license agreement with Johnson & Johnson for the development and commercialization of MGD011.
MGNX: 33.00 (+0.34), JNJ: 104.59 (+0.31), MDCO: 27.06 (+0.21), BMY: 59.15 (-0.01), FPRX: 26.12 (+0.07)

3 Clinical Stage Biotech Stocks That Should Be on Your Watchlist in 2015
Motley Fool Staff - Motley Fool - Tue Dec 23, 6:07AM CST
Source: Celgene Corp Biotech stocks are notorious for their stratospheric gains and subterranean losses, especially clinical stage biotech stocks that develop promising, yet unproven, next-generation drugs. Those emerging biotech stocks may offer...
BLUE: 88.76 (+3.23), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), NVS: 93.91 (+0.66), CELG: 109.60 (+3.48), FPRX: 26.12 (+0.07), EXEL: 1.29 (-0.01)

Is Five Prime Therapeutics (FPRX) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:39AM CST
Five Prime Therapeutics is one stock that might be an intriguing choice for investors right now as it is seeing solid earnings estimate revision and has a Zacks Industry Rank of 51
FPRX: 26.12 (+0.07)

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Seattle Genetics down on ASH presentations
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 11:37AM CST

SGEN: 31.10 (-0.14), AZN: 70.44 (+0.26), MRK: 57.46 (+0.25), BMY: 59.15 (-0.01), CELG: 109.60 (+3.48), FPRX: 26.12 (+0.07)

Five Prime Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference
GlobeNewswire - Fri Dec 05, 1:39AM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer of Five Prime, will present at the Oppenheimer 25 Annual Healthcare Conference on Wednesday, December 10 at 3:55 PM Eastern Time. The conference will take place at the Crowne Plaza Hotel in New York City.
FPRX: 26.12 (+0.07)

Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Trial Evaluating FPA144 in Gastric Cancer
GlobeNewswire - Thu Dec 04, 3:05PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that the company has initiated dosing in its Phase 1 clinical trial of FPA144, an anti-FGF receptor 2b antibody. FPA144 is designed to inhibit tumor growth by preventing the binding of certain fibroblast growth factors to FGF receptor 2b (FGFR2b) and directly kill tumor cells in a process called antibody-dependent cell-mediated cytotoxicity (ADCC). FPA144 is being developed initially as a monotherapy for refractory gastric cancer, a significant unmet medical need that may warrant an accelerated development and registration path.
FPRX: 26.12 (+0.07)

Insider Trading Alert - DATA, LNKD And FPRX Traded By Insiders
at The Street - Wed Dec 03, 10:15AM CST
Stocks with insider trader activity include DATA, LNKD and FPRX
LNKD: 231.83 (+0.34), DATA: 88.76 (+0.04), FPRX: 26.12 (+0.07)

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014
M2 - Tue Dec 02, 6:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/53cpct/chronic) has announced the addition of the "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 100 companies are cited in this text including: - Ache Laboratorios Farmaceuticos S/A - Adamis Pharmaceuticals Corporation - Advinus Therapeutics Ltd. - AIM Therapeutics Inc. - Axikin Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Daiichi Sankyo Company, Limited - Errant Gene Therapeutics, LLC - Five Prime Therapeutics, Inc. - GlaxoSmithKline plc - Hydra Biosciences, Inc. - iCeutica, Inc. - Johnson & Johnson - KaloBios Pharmaceuticals, Inc. - Medestea Research & Production S.p.A. - Novartis AG - Ockham Biotech Limited - Pfizer Inc. - PharmaLundensis - Re-Pharm - Seoul Pharma - Takeda Pharmaceutical Company - Zambon Company For more information visit http://www.researchandmarkets.com/research/53cpct/chronic
JNJ: 104.59 (+0.31), KBIO: 1.63 (-0.04), PFE: 31.42 (-0.03), ADMP: 5.17 (+0.06), GSK: 42.85 (+0.11), NVS: 93.91 (+0.66), FPRX: 26.12 (+0.07)

The Zacks Analyst Blog Highlights:BioMarin, Prosensa, Five Prime Therapeutics, AbbVie, Amgen, Biogen and Vertex
PR Newswire - Fri Nov 28, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the BioMarin (Nasdaq:BMRN-Free Report), Prosensa (Nasdaq:RNA-Free Report), Five Prime Therapeutics (Nasdaq:FPRX-Free Report), AbbVie (NYSE:ABBV-Free Report), Amgen (Nasdaq:AMGN-Free Report), Biogen (Nasdaq:BIIB-Free Report) and Vertex (Nasdaq:VRTX-Free Report).
AMGN: 160.67 (+3.15), FPRX: 26.12 (+0.07)

Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST

HTBX: 4.18 (-0.22), BIB: 122.51 (+3.83), INCY: 71.57 (+1.99), PFE: 31.42 (-0.03), IBB: 299.80 (+5.12), DRGS: 53.60 (unch), BIND: 5.73 (+0.06), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), ONTY: 1.89 (+0.01), ECYT: 6.33 (+0.24), BIS: 47.26 (-1.74), CLVS: 54.58 (+0.43), AZN: 70.44 (+0.26), MRK: 57.46 (+0.25), ARIA: 6.81 (+0.15), IRY: 47.28 (-0.01), IXJ: 100.54 (+0.55), FPRX: 26.12 (+0.07)

Five Prime Therapeutics Up on Deal with Bristol-Myers - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 3:30PM CST
Five Prime Therapeutics, Inc. announced that it has entered into an agreement with Bristol-Myers Squibb Company.
ACT: 254.20 (-1.68), AMAG: 43.02 (+0.90), BMY: 59.15 (-0.01), FPRX: 26.12 (+0.07)

Biotech Stock Roundup: BioMarin to Acquire Prosensa, AbbVie HCV Therapy Closer to EU Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 9:54AM CST
BioMarin's (BMRN) high risk - high reward decision to acquire Prosensa (RNA) was a key event in the biotech sector last week.
BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10), AMGN: 160.67 (+3.15), ABBV: 66.21 (+1.86), FPRX: 26.12 (+0.07)

Five Prime Therapeutics to Present at The 26th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 25, 3:11PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer of Five Prime, will present at the 26 Annual Piper Jaffray Healthcare Conference on Wednesday, December 3 at 12:30 PM Eastern Time. The conference will take place at the Palace Hotel in New York City.
FPRX: 26.12 (+0.07)

Five Prime Therapeutics, Inc. (FPRX) in Focus: Stock Soars 31.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 8:18AM CST
Five Prime Therapeutics, Inc. (FPRX) was a big mover last session, as the company saw its shares rise by over 31% on the day.
ANIP: 55.24 (+1.79), AMAG: 43.02 (+0.90), AFFX: 9.80 (+0.05), FPRX: 26.12 (+0.07)

Lions Gate and Tesla are big market movers
AP - Mon Nov 24, 3:48PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
TSLA: 222.26 (+1.29), RNA: 18.76 (+0.10), UTX: 116.91 (-0.30), LGF: 32.36 (+0.49), TSL: 8.55 (+0.10), XOM: 93.78 (-0.81), FPRX: 26.12 (+0.07), DENN: 9.96 (+0.05)

Five Prime in cancer drug deal with Bristol-Myers
AP - Mon Nov 24, 3:20PM CST
NEW YORK (AP) — Five Prime Therapeutics said Monday that it will study a cancer drug regimen that combines one of its drugs with a therapy developed by Bristol-Myers Squibb.
BMY: 59.15 (-0.01), FPRX: 26.12 (+0.07)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 11:46AM CST

CIMT: 8.81 (unch), CLRB: 3.02 (-0.05), MPX: 8.00 (-0.03), FATE: 4.90 (+0.23), TTPH: 38.86 (+0.53), PHMD: 1.46 (-0.03), BIND: 5.73 (+0.06), AXPW: 1.00 (-0.04), CANF: 3.70 (+0.01), SYN: 1.46 (-0.07), RNA: 18.76 (+0.10), CLIR: 7.63 (+0.16), VSCI: 0.76 (-0.07), OCRX: 5.77 (+0.02), GALE: 1.49 (-0.02), REI: 10.95 (+0.22), OGEN: 0.90 (-0.07), PTP: 73.65 (-0.03), FPRX: 26.12 (+0.07)

Bristol-Myers and Five Prime team up in cancer
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 8:29AM CST

BMY: 59.15 (-0.01), FPRX: 26.12 (+0.07)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 139

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 161

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 158

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 71

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 129

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 111

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 104

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 125

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 142

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading

Top 5 Most Recently Viewed Articles

Unleashing Innovations: The Growth of Chronic Venous Insufficiency Treatments

Updated Category News Views 216

Chronic Venous Insufficiency Market Dynamics Chronic venous insufficiency (CVI) is a common public health concern that affects circulation in the lower limbs. Recent projections indicate a remarkable growth trend, expecting a compound annual growth rate (CAGR) of 9.4% from 2025 to 2034. This uptick stems from the advent of groundbreaking therapies and advanced medical...

Continue Reading
BSTR Miner Unveils Smart Contract Mining for All Investors

Updated Category News Views 343

BSTR Miner Introduces Innovative Smart Contract Mining Service BSTR Miner stands out as a premier cloud mining platform, now proudly offering its new smart contract mining service. This revolutionary service aims to streamline the often-complex world of traditional mining by integrating AI-driven dynamic profit optimization, automated contract generation, and elastic...

Continue Reading
UKG Expands Global Presence with New Operations Hub in Ireland

Updated Category News Views 256

UKG Expands Its Presence in Ireland UKG, a leading provider of HR, payroll, workforce management, and culture solutions, has unveiled plans for its new Global Operations Hub in Kilkenny, Ireland. This exciting initiative includes the creation of around 200 new jobs, primarily focusing on cybersecurity. This move reflects UKG's dedication to expanding its operations and...

Continue Reading
Cathie Wood's Bold Moves: Selling Off Block and Moderna Shares

Updated Category News Views 162

Cathie Wood's Strategic Moves with Ark Invest Cathie Wood, the founder and CEO of Ark Invest, is known for her bold investment strategies, especially concerning innovative companies. Recently, her firm made notable trades with Block Inc and Moderna, hinting at her current viewpoint in the fast-evolving investment landscape. Significant Trade with Block Inc In the last...

Continue Reading
Eurocastle Highlights Leadership Share Transactions and Vision

Updated Category News Views 132

Eurocastle Investment Limited Announces Key Share Transactions EUROCASTLE INVESTMENT LIMITED Contact: Oak Fund Services (Guernsey) Limited Company Administrator Attn: Nicole Barnes Tel: +44 1481 752957 Eurocastle announces Director/PDMR Dealing Notification In line with obligations under relevant regulations, Eurocastle Investment Limited has shared significant updates...

Continue Reading